- Home
- DMII vs ALLO Comparison
DMII vs ALLO Comparison
Compare DMII & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
N/A
Current Price
$2.09
Company Overview
Basic Information| Metric | DMII | ALLO |
|---|---|---|
| Founded | 2024 | 2017 |
| Country | United States | United States |
| Employees | N/A | 152 |
| Industry | Blank Checks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 641.5M | 722.1M |
| IPO Year | 2025 | 2018 |
Fundamental Metrics
Financial Performance| Metric | DMII | ALLO |
|---|---|---|
| Price | $10.14 | $2.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 15 |
| Target Price | N/A | ★ $8.35 |
| AVG Volume (30 Days) | 46.1K | ★ 5.9M |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 34.09 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $142,416.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.87 | $1.04 |
| 52 Week High | $10.20 | $4.46 |
Technical Indicators
Market Signals| Indicator | DMII | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 67.04 | 54.73 |
| Support Level | $10.06 | $2.07 |
| Resistance Level | $10.20 | $2.25 |
| Average True Range (ATR) | 0.02 | 0.11 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 50.00 | 65.85 |
Price Performance
Historical Comparison DMII
ALLO
About DMII Drugs Made In America Acquisition II Corp. Ordinary Shares
Drugs Made In America Acquisition II Corp is a blank check Company.
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).